<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7177">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03013491</url>
  </required_header>
  <id_info>
    <org_study_id>CTMX-M-072-001</org_study_id>
    <nct_id>NCT03013491</nct_id>
  </id_info>
  <brief_title>PROCLAIM-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas</brief_title>
  <official_title>An Open-Label, Dose-Finding and Proof of Concept Study of the PD-L1 Probody™ Therapeutic , CX-072, as Monotherapy and in Combination With Yervoy (Ipilimumab) or With Zelboraf (Vemurafenib) in Subjects With Advanced or Recurrent Solid Tumors or Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytomX Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytomX Therapeutics</source>
  <brief_summary>
    <textblock>
      The purpose of this first-in-human study of CX-072 is to characterize the safety,
      tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072
      administered intravenously (IV) as a single agent or in combination with ipilimumab or
      vemurafenib in adult subjects with advanced or recurrent solid tumors or lymphomas.
      PROCLAIM-001: PRObody CLinical Assessment In Man CX-072 clinical trial 001

      CX-072 is a Probody™ therapeutic directed against PD-L1 (programmed cell death ligand 1).
      Probody therapeutics are proteolytically-activatable antibodies (Abs) designed to widen the
      therapeutic index by minimizing drug interaction with normal tissue while retaining
      anti-tumor activity. Probody therapeutics are &quot;masked&quot; to attenuate binding to target in
      healthy tissue but can become &quot;unmasked&quot; in the tumor microenvironment by tumor-specific
      protease activity.

      PROBODY is a trademark of CytomX Therapeutics, Inc.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects experiencing a dose limiting toxicity at various dose levels when given multiple doses of CX-072 as a monotherapy or in combination with ipilimumab or vemurafenib</measure>
    <time_frame>28 days (dose limiting toxicity period)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects experiencing anti-cancer activity (ORR) at various dose levels when given multiple doses of CX-072 as a monotherapy or in combination with ipilimumab or vemurafenib</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>CX-072</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy CX-072</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CX-072 with Ipilimumab #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination CX-072 + ipilimumab (Schedule 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CX-072 with Ipilimumab #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination CX-072 + ipilimumab (Schedule 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CX-072 with Vemurafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination CX-072 + vemurafenib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CX-072 expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy CX-072 expansion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CX-072</intervention_name>
    <arm_group_label>CX-072</arm_group_label>
    <arm_group_label>CX-072 with Ipilimumab #1</arm_group_label>
    <arm_group_label>CX-072 with Ipilimumab #2</arm_group_label>
    <arm_group_label>CX-072 with Vemurafenib</arm_group_label>
    <arm_group_label>CX-072 expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ipilimumab</intervention_name>
    <arm_group_label>CX-072 with Ipilimumab #1</arm_group_label>
    <arm_group_label>CX-072 with Ipilimumab #2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vemurafenib</intervention_name>
    <arm_group_label>CX-072 with Vemurafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed diagnosis of metastatic or advanced unresectable tumors that
             progressed on standard therapy

          2. Agreement to provide mandatory archival tissue or fresh biopsy.

          3. At least 18 years of age.

        Exclusion Criteria:

          1. Prior therapy with a chimeric antigen receptor (CAR) T-cell containing regimen.

          2. History of severe allergic or anaphylactic reactions to human monoclonal antibody
             therapy or known hypersensitivity to any Probody therapeutic.

          3. Active or history of uveal, mucosal, or ocular melanoma. Human immunodeficiency virus
             (HIV) or acquired immune deficiency syndrome (AIDS)-related illness, chronic
             hepatitis B or C.

          4. History of or current active autoimmune diseases, including but not limited to
             inflammatory bowel diseases, rheumatoid arthritis, autoimmune thyroiditis, autoimmune
             hepatitis, systemic sclerosis, systemic lupus erythematosus, autoimmune vasculitis,
             autoimmune neuropathies, or type 1 insulin dependent diabetes mellitus.

          5. History of syndrome or medical condition(s) that requires systemic steroids (&gt; 10 mg
             daily prednisone equivalents) or immunosuppressive medications.

          6. History of allogeneic tissue/solid organ transplant, prior stem cell or bone marrow
             transplant.

          7. Chemotherapy, biochemotherapy, radiation or immunotherapy or any investigational
             treatment within 30 days prior to receiving any study drug.

          8. Major surgery (requiring general anesthesia) within 3 months or minor surgery
             (excluding biopsies conducted with local/topical anesthesia) or gamma knife treatment
             within 14 days (with adequate healing) of administration of any study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Will, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>CytomX Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lori Carman</last_name>
    <email>clinicaltrials@cytomx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PROCLAIM Investigative Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>PROCLAIM Investigative Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PROCLAIM Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PROCLAIM Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PROCLAIM Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>PROCLAIM Investigative Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 24, 2017</lastchanged_date>
  <firstreceived_date>December 26, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>checkpoint inhibitor</keyword>
  <keyword>monotherapy</keyword>
  <keyword>combination</keyword>
  <keyword>PD-L1</keyword>
  <keyword>CTLA-4</keyword>
  <keyword>solid tumor</keyword>
  <keyword>lymphoma</keyword>
  <keyword>BRAF</keyword>
  <keyword>PROCLAIM</keyword>
  <keyword>CX-072</keyword>
  <keyword>PROCLAIM-072</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
